The House of Representative today passed two AHA-supported bills to promote generic and biosimilar competition in the prescription drug market. The Orange Book Transparency Act (H.R. 1503) and Purple Book Continuity Act (H.R. 1520) would increase the accuracy and transparency of the two databases that guide development decisions for generic and biosimilar manufacturers.

Related News Articles

Headline
AHA’s Institute for Diversity and Health Equity March 27 began sending hospitals and health systems an email reminder to complete the 2024 DEI Benchmark Survey…
Headline
AHA March 26 submitted comments on a discussion draft of the SUSTAIN 340B Act, legislation proposed in the Senate to clarify Congress’ intent in creating the…
Headline
President Biden March 24 signed legislation funding the rest of the federal government through Sept. 30, including Department of Health and Human Services…
Headline
The House and Senate Appropriations committees March 20 released the Further Consolidated Appropriations Act of 2024, legislation that would fund all remaining…
Headline
The House Energy and Commerce Committee March 20 unanimously passed AHA-supported legislation to reauthorize through 2029 the Dr. Lorna Breen Health Care…
Headline
The Department of Health and Human Services’ Office for Civil Rights March 18 released updated guidance for HIPAA-covered entities and business associates on…